Wolfgang Schroeder’s Post

Thoughts on this? >> SiteOne Therapeutics, a pain biotech that's partnered with Vertex, nabs $100M >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #biotech #productmarketing #pharma #healthcare

Thoughts on this? >> SiteOne Therapeutics, a pain biotech that's partnered with Vertex, nabs $100M >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #healthcare #pharmaceutical #pharma #biotech

🔬Iambic Therapeutics introduces Enchant: an AI-driven tool designed to streamline drug development by predicting clinical success earlier in the process. Read the full article here: https://lnkd.in/djMPBrgG

Tryp Therapeutics Ltd (ASX:TYP, OTC:TYPTF) CEO Jason Carroll joins Proactive’s Tylah Tully to talk through $6 million the company has secured through a strategic placement of 300 million new shares at $0.02 each. The placement was supported by new and existing stakeholders, including #cornerstoneinvestors, the #MerchantBiotechFund and Dr Daniel Tillett, who will join the board as a non-executive director. Key shareholders and company executives, including Carroll himself, also participated. The funds will facilitate the accelerated #clinicaldevelopment of #TRP8803, an #IVinfusedpsilocin formulation designed to address limitations associated with #oralpsilocybin dosing. Benefits of TRP-8803 include faster onset, more controlled dosing and shorter intervention times. This aligns with Tryp’s ongoing efforts to explore the compound’s therapeutic potential in treating various conditions. Watch at #Proactive #ProactiveInvestors #psilocybin #psilocin #ASX #biotech http://ow.ly/YF8o105Nm5G

With so much interest in oral GLP-1s across the industry, now is the perfect time to dive into the biopharmaceutical considerations behind their development 🚀 I'm excited to share a link to our upcoming webinar, where we'll explore the key factors shaping this growing area of research. Don't miss this opportunity to hear from the experts and stay ahead in this rapidly evolving field! #QuotientSciences #Webinar #GLP1 #OralTherapeutics #DrugDevelopment

This is your final chance to sign up for our upcoming webinar! Join our experts for an insightful discussion on the key aspects to consider for CMC testing for protein-based therapeutics. Save your seat now! Link  👉 https://bit.ly/4cc59hu #drugdevelopment #biologicstesting #biopharmatesting #SGSNorthAmerica

Our very own Associate Director of CMC, Ashley Taylor, highlighted this article by LifeTein.com on the benefits of stapled peptides. Stapled peptides are breaking new ground in drug development, offering enhanced stability and efficacy for targeting previously undruggable interactions. What are your thoughts on the future of peptide therapeutics? Check out the article and let us know! https://lnkd.in/embS6_di #BiotechInnovation #PeptideTherapeutics #DrugDevelopment

𝗖𝗼𝗻𝘁𝗶𝗻𝗲𝘂𝗺 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 𝗳𝗶𝗹𝗲𝘀 𝗳𝗼𝗿 𝗜𝗣𝗢 𝘄𝗶𝘁𝗵 𝗠𝗦 𝗱𝗿𝘂𝗴 𝗶𝗻 𝗣𝗵𝗮𝘀𝗲 𝗜𝗜 Clinical-stage biotech Contineum Therapeutics, which until recently went by the name Pipeline Therapeutics, on Friday revealed plans to go public under the Nasdaq ticker $CTNM. The biotech’s drug PIPE-307 is being studied in patients with relapsing-remitting multiple sclerosis, or RRMS. It’s in Phase II, fitting the profile of IPO that investors have been seeking after two dismal years of new entrants to the market. Carmine Stengone. https://lnkd.in/e2Y_q8wS

🚨A reminder to register for the upcoming webinar on how to accelerate the development and production of AAV-based therapeutics!  Learn from Regeneron’s Marília Barros and Refeyn’s Matthew Ranaghan about the best analytical strategies to analyze the ratios of empty/full/partial AAV ratios, capsid titers, sample purity and other key quality attributes essential for successful drug development. And of course, how to integrate #MassPhotometry in your workflows for fast, sample-efficient analysis. 🔬📊  Register here 👉 https://lnkd.in/dfMqa7dY

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small molecules and systemic indications. Watch this video to learn how Catalent can help meet the needs of inhalation innovators and accelerate time to market. https://ow.ly/3Co050Um6mX